Optimal management of patients with relapsed/refractory CLL is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide and rituximab (FCR) for previously treated patients with CLL and identify patients who benefit most from this therapy. We explore efficacy of FCR in patients beyond first relapse, patients with prior exposure to fludarabine and alkylating agent combinations and patients with prior exposure to rituximab. The FCR regimen was administered to 284 previously treated patients with CLL. Patients were assessed for response and progression by 1996 NCI-WG criteria for CLL and followed for survival. The overall response rate was 74%, with 30% complete remission. The estimated median overall survival was 47 months and median progression-free survival for all patients was 21 months. Subgroup analyses indicated that the following patients were most suitable for FCR treatment: patients with up to 3 prior treatments, fludarabine-sensitive patients irrespective of prior rituximab exposure, and patients without chromosome 17 abnormalities. FCR is an active and well-tolerated therapy for patients with relapsed CLL. The addition of rituximab to FC improved quality and durability of response in this patient population.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a B cell malignancy with significant variability in clinical course depending on patients' disease characteristics, treatment and response to prior treatment. Despite highly active treatment agents and combinations, no curative standard treatment is available. Stem cell transplant is promising for long-term disease control and potential for cure; however, it is not a treatment modality available to most patients and has significant associated toxicities and morbidity. 1, 2 Most patients receive intermittent treatment with periods of remission or stable disease that are typically shorter with each intervention and many patients acquire treatment resistance with low response rates and short response duration and survival. [3] [4] [5] [6] Identifying therapeutic interventions for relapsed and refractory patients that result in long-term remission is a challenging aspect in the management of CLL. 7 Purine analogue combined with alkylating agent improves the quality of response over single-agent therapy and is associated with longer progression-free survival (PFS) in previously treated and untreated patients with CLL. [8] [9] [10] Although standard-dose rituximab monotherapy has only modest efficacy in CLL, when combined with fludarabine (F) there is synergism based on modulated levels of complement-resistance proteins and of anti-apoptotic factors, such as Bcl-2. 11, 12 Monoclonal antibodycontaining chemoimmunotherapy regimens including rituximab improve quality and duration of responses in CLL. [13] [14] [15] The chemoimmunotherapy combination of fludarabine, cyclophosphamide, and rituximab (FCR) has become a standard treatment for CLL based on the German CLL Study Group (GCLLSG) frontline CLL8 trial and the For personal use only. on October 24, 2017. by guest www.bloodjournal.org From International REACH trial for patients in first relapse. 13, 15 However, the REACH trial excluded patients in second or subsequent relapse and those previously treated with rituximab or fludarabine and cyclophosphamide (FC) combination; therefore, there is limited understanding of the efficacy of the FCR regimen in such patient populations.
We previously reported results of FCR chemoimmunotherapy for relapsed and refractory patients with CLL. 16 This regimen had a high response rate in relapsed patients and was a significant advance compared to that seen in historic patients treated with FC or F. 9 We report a final analysis of this Phase II trial; and present responses, response duration and survival for 284 relapsed patients treated with FCR.
The prolonged follow-up enables us to determine patient pretreatment characteristics associated with superior outcomes after therapy to identify relapsed patients most appropriate for this regimen.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From . Refractoriness to fludarabine and alkylating agent was defined as failure to achieve at least a PR with the last fludarabine-and alkylating agent-based treatment, respectively, or progression within 6 months of treatment.
MATERIALS AND METHODS
The
Treatment
Details of study and treatment plans were previously reported. 16 The ratio of IGHV to RAS (PCR ratio) was calculated and used to quantify the levels of residual disease. A ratio of 0.001 to 0.10 was considered to be low positive, higher ratios were considered to be positive and lower ratios were considered negative.
Adverse events (AEs) and serious adverse events (SAEs) were documented according to the CTC version 2.0.
Statistical Considerations
The primary objective was to improve the complete remission (CR) rate compared to that seen with historic regimens of FC and F. As pre-treatment characteristics such as cytogenetic analysis were likely to be important in determining treatment outcomes, the original study design was extended to allow accrual of up to 300 patients to allow for subset analysis. Overall survival (OS), progression-free survival (PFS) and time-toprogression (TTP) were secondary outcomes calculated from the first day of therapy.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Actuarial survival, PFS and TTP were estimated using the methods of Kaplan and Meier and survival estimates were compared among subgroups of patients using the log-rank test. Fisher's exact test (two-tailed) was utilized to analyze differences in response outcomes by pre-treatment characteristics. Associations between CR and OR and patient pretreatment characteristics were evaluated using univariable and multivariable logistic regression models. Associations between patient pretreatment characteristics and time-to-event endpoints were analyzed using Cox proportional hazards regression models. There were 24 pretreatment variables analyzed and therefore a negative stepwise analysis was performed with a p-value cut-off of p<0.05. All computations were carried out using SAS, S-plus and Statistica (Stat-Soft).
FC comparison group
Patients enrolled at MDACC on clinical trials of FC as a salvage therapy for CLL were included as a historical comparison group (n=114). A multivariate Cox regression analysis was utilized to adjust for differences in pretreatment characteristics and define the impact of therapy on progression free and overall survival.
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RESULTS

Patients
There were 284 relapsed or refractory patients with CLL entered into this study; the median age was 60 years and median number of prior treatments was 2 (1-10). Other pretreatment characteristics are shown in Tables 1 and 2 . Patients were ranked according to karyotype risk group using a similar hierarchical classification system utilized by Dohner et al. 22 such that patients with abnormality of chromosome 17 were ranked in the highest risk group and patients with diploid karyotype or 13q deletion were in the lowest risk group. Patients with more than 2 cytogenetic abnormalities other than an abnormality in chromosome 17 were classified
Response to Therapy
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From as complex and patients with karyotypic abnormalities not included in the Dohner classification were grouped as "others" (Table 1) . Patients with diploid karyotype or 13q deletion as a sole abnormality by metaphase karyotype had the highest likelihood for response with an OR of 82% and 34% of patients achieving CR. In contrast, patients with an abnormal chromosome 17 by metaphase karyotype (n=20) demonstrated particularly poor responses to therapy with an ORR of 35% and only 1 patient (5%) who achieved nPR (Table 1) .
Superior outcomes for time-to-event endpoints were observed for patients who achieved CR or nPR. Therefore, we analyzed characteristics associated with a higher likelihood of CR or nPR by univariable analyses, as shown in Supplemental Table 1 . In a multivariable model, pretreatment characteristics independently associated with a higher likelihood of achieving CR or nPR were younger age, lower β-2 microglobulin (β2M), higher hemoglobin, no fludarabine-refractoriness, lower number of prior treatments, and higher platelet count (Supplemental Table 3 ). Pretreatment characteristics associated with a higher likelihood of overall response by univariable analysis are shown in Supplemental Table 2 . In a multivariable model, patients not resistant to fludarabine, with higher hemoglobin and platelet count, lower serum creatinine and absence of chromosome 17 or complex cytogenetic abnormalities had a higher probability of achieving an overall response (Supplemental Table 3 ).
Progression-Free Survival
The estimated median PFS was 20.9 months (95% CI, 18.8-27.6 months) for the whole cohort of patients (n=284). At the time of analysis, 223 patients (79%) experienced disease progression or died ( Figure 1 ). The estimated median PFS for patients achieving CR was 60 months compared to 38 months for patients achieving nPR (p=0.076) and 15 months for those achieving PR (p<0.001) (Figure 2a ). Pretreatment characteristics that correlated with longer PFS by univariable analysis are displayed in Supplemental Table 4 . In multivariable analysis, pretreatment patient characteristics independently associated with lower risk of disease progression or death included lower serum creatinine, lower lactate dehydrogenase (LDH), higher platelet count, higher serum albumin, lower number of prior treatments and fludarabine sensitivity ( Table 4 ).
The presence of unfavorable chromosome abnormalities (11q deletion, chromosome 17 or complex abnormalities) was also associated with shorter PFS (Figure 2c ). After including karyotype in the regression analysis (n=177), the following were independently associated with longer PFS: lack of unfavorable karyotype, lower serum creatinine, higher platelets, lower number of prior treatments and no prior refractoriness to fludarabine (Table 4) . (Table 4) . Causes of mortality are detailed in Supplemental Table 6 . Infection and progressive CLL were the most common causes of mortality.
Time to Progression and Minimal Residual Disease
Number of courses of therapy to achieve a response
Of 224 patients who received at least 3 courses of FCR; 211 had an evaluable response assessment after 3 courses, including 29 CR (14%), 39 nPR (18%), 112 PR (53%) and 31 patients with no objective response. There were 142 patients with response evaluation both after 3 courses and 5 or more courses of therapy; 66 (46%) patients improved their response including 28 from PR to CR, 19 PR to nPR, 19 nPR to CR and 3 achieving a PR. Due to the small patient numbers confirmed to be in MRD-
negative CR (n=31) after 3 courses, our study was not powered to detect differences in remission duration or survival between patients who received 6 courses of FCR and those patients who received less.
Toxicity
One hundred and twenty patients (42%) completed all 6 courses of FCR, 103 (36%) received full-dose; 169 (60%) received more than 3 courses. At least one dose reduction was required for 42 patients. Patients over 70 years were significantly less likely to complete 3 or more courses of therapy when compared to younger patients with 5 of 40 patients (13%) over the age of 70 years completing 6 courses and 11 (28%) receiving more than 3 courses of FCR (Figure 4) . The most common reasons for early treatment cessation were myelosuppression, infection, and lack of response (supplemental Table 7 ). In a multivariate analysis, patient pre-treatment characteristics independently associated with lower likelihood of completing all 6 courses included having received more than 3 prior chemotherapy regimens and age over 70 years.
Patients who had received up to 3 prior regimens were also less likely to complete 6 courses of therapy if they had Rai stage IV disease prior to FCR; however, Rai stage was not an independent factor in patients who had received more than 3 prior therapies.
The most common toxicity was hematologic, with grade 3 and 4 neutropenia complicating 22% and 34% of treatment courses, respectively. The rate of grade 3 or 4 neutropenia remained consistent across courses. Grade 3 and 4 thrombocytopenia was associated with 12.5% and 7.0% of treatment courses, respectively. By CTC v2.0
anemia was associated with 11.2% of treatment courses; grade 3 or 4 anemia was rare (0.46%). Using CTC v2.0 criteria, anemia is calculated as a proportional decrease from baseline and therefore may underestimate proportion of anemia with hemoglobin less than 8 g/dl. Using CTC v3.0 grading criteria for anemia, grade 3 and 4 anemia was noted in 7.1% and 4.7% of treatment courses, respectively (Supplemental Table 8 ). There were 18 (6%) patients who developed clinically significant autoimmune hemolytic anemia that required treatment during or after therapy including 3 patients who had evidence of active hemolysis prior to therapy.
Serious infections were defined as grade 3 or 4 infections by CTC v2.0 grading criteria.
The most common serious infections were sepsis and pneumonia, associated with 1.0% Herpes simplex virus and herpes zoster reactivation were associated with 0.8% and 0.7% of courses, respectively. Elderly patients were more likely to discontinue therapy prior to 6 courses following an infectious event; 24% of patients 70 years or older discontinued therapy following an infection compared to 9% of younger patients (Supplemental Table 9 ). We identified subgroups of patients with favorable outcomes following treatment with FCR. These analyses aimed to identify relapsed patients for whom FCR was beneficial. This is particularly important since the REACH trial excluded patients who had received more than 1 prior treatment and those previously treated with either FC or rituximab.
Patients in our study who had received 3 or fewer prior therapies, not resistant to fludarabine or patients without high-risk cytogenetic abnormalities (presence of chromosome 17 or complex cytogenetic abnormalities) demonstrated better response duration and survival after therapy.
In order to explore the effect of prior therapy on response, we developed a hierarchical model exploring the likelihood of response according to the intensity of prior treatment.
Patients who were previously exposed to antibody therapy, including rituximab, or purine analogues but not alkylating agents had the highest response rates and survival.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Therefore, these patients are ideal candidates for salvage therapy with FCR. In our hierarchy, patients previously exposed to fludarabine and alkylating agents, either sequentially or concurrently, demonstrated acceptable response rates as long as they were not fludarabine-refractory. In these patients, FCR would still be considered a reasonable treatment option. Patients refractory to fludarabine or those who had received more than 3 prior therapies experienced short PFS. Such patients are likely to demonstrate poor responses with currently available chemotherapy regimens and should be considered for investigational therapies or stem cell transplant when available. 13, 25 Patients with 11q deletion demonstrated shorter PFS and OS when compared to lowrisk cytogenetic groups; however, in the REACH trial, patients with 11q deletion by FISH experienced significantly longer PFS after FCR when compared to FC. 13 The benefit of adding rituximab to FC in patients with 11q deletion was also noted in the GCLLSG frontline CLL8 trial. 15 In our study 11q deletion was defined by metaphase karyotype whereas in the two randomized trials 11q deletion was identified by FISH analysis. In addition patients with 11q deletion in our study were a highly pre-treated group of patients who had received a median of 3 prior treatments. This small subgroup of patients is therefore not comparable to the patients in the REACH trial. Based on the results of the REACH study patients with 11q deletion should be considered for salvage therapy with FCR.
The lack of data on newer prognostic markers is a limitation of this study. Unmutated IGHV gene status was independently associated with shorter PFS and TTP in a multivariable analysis; however we did not incorporate this into our multivariate model due to the high number of missing values. There were an insufficient number of patients with FISH or ZAP70 results for meaningful multivariable statistical analyses.
Due to the age of this study, few patients in our study had received prior FCR; however, we demonstrate in this study that FCR is an effective therapy after FC if patients were not refractory to this therapy. In a recent analysis of patients who relapsed after the frontline FCR study by Keating et al., patients who were retreated with FCR as first salvage experienced durable responses if they experienced a response duration of at least three years after the initial regimen. 26 Retreatment with FCR should be considered cautiously in elderly patients with CLL due to the potential for prolonged myelotoxicity. From this data, younger patients with an initial response for at least 3 years after frontline FCR may be successfully retreated with salvage FCR.
This study was not designed to assess the optimal number of courses of FCR for patients with relapsed CLL. All patients were expected to receive 6 courses unless they had toxicity or lack of response, therefore comparison of patients who completed therapy prior to 6 courses to those who completed planned therapy is confounded by selection of patients with toxic events or inadequate responses causing early cessation of treatment. A controlled clinical trial should be conducted to explore the optimal number of courses of FCR in patients who achieve a flow cytometry negative CR after 3
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From courses. This is of particular relevance in the relapsed setting as cumulative myelotoxicity following chemotherapy may have a relatively greater impact on survival than in frontline therapy. A significant number of patients who achieved a PR after 3 courses of therapy did improve their response to nPR or CR after 5 or 6 courses of therapy. In the absence of further evidence it is reasonable to continue therapy for patients who tolerate therapy and achieve a PR after 3 courses.
Minimal residual disease (MRD) measurement has become an increasingly important tool in determining response to chemotherapy or chemoimmunotherapy in CLL. MRD negativity using high-sensitivity flow cytometry following therapy has been associated with longer time to progression and survival after therapy.
27-30 Although we utilized flow cytometry to further assess patients with complete remissions; our 2-colour flow cytometry assay is limited by low sensitivity in identifying residual CLL cells compared to newer protocols which are able to detect around 1 in 10,000 residual CLL cells. This lack of sensitivity and in particular the low numbers of flow positive CR limited our ability to detect significant differences in survival outcomes between MRD positive and negative patients. MRD assessment was also performed utilizing a PCR assay of higher sensitivity than 2-colour flow cytometry. The results of this assay were also limited by the lower number of patients with MRD-positive CR. In addition, computerassisted tomography scans were not performed to confirm responses which may have led to patients assessed clinically as CR as having residual CLL in abdominal or other lymph node areas. Future studies assessing outcomes in MRD patients should utilize
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From newer more sensitive and standardized approaches for MRD measurement as described by the European Research Initiative on CLL (ERIC). 31 Patients over 70 years were under-represented in this study. Elderly patients were less likely to complete more than 3 courses of FCR, had a lower CR rate and experienced more infectious complications. Fludarabine-based combinations are associated with high incidence of myelosuppression and toxicity in elderly patients. 32 Patients in this study did not routinely receive growth factor support and this may have played a role in the ability of this group of patients to tolerate therapy. Although patients were required to have good performance status, assessment of co-morbidities was not required for protocol entry and may also impact the ability of elderly patients to tolerate FCR.
Further research is needed to determine the role of dose-reduced FCR, 33 pentostatin, cyclophosphamide and rituximab (PCR) 24 or bendamustine and rituximab 34 in elderly patients with relapsed CLL. We recommend this regimen be used with caution in patients over the age of 70, with assessment of co-morbidity status, dose-adjustments and consideration of growth factor support. [35] [36] [37] FCR is an effective and safe therapy in patients without high-risk features (refractory to therapy or chromosome 17 abnormalities). Whereas the REACH trial confirmed the benefit gained by the addition of rituximab in CLL patients in first salvage after single agent (F or C) therapy, 13 A.
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